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Abstract. It is now widely accepted that human neoplasms 
arise as a result of a sequence of mutations affecting the 
structure of genes involved in growth control. Identifying the 
nature of such genetic mutations in thyroid neoplasms and 
their prevalence in the various tumor phenotypes is critical to 
the understanding of their pathogenesis. Mutational 
activation of ras oncogenes has been associated with human 
thyroid neoplasia. We examined the expression of ras 
oncogene in benign hyperplastic or inflamatory lesions of the 
goiter, as well as in benign and malignant thyroid tumors. 
Although no significant differences of ras oncogene 
expression was found between benign and malignant lesions, 
the overexpression in proliferative areas generally suggests 
the possible involvement of ras oncogene in the trophic 
hormone control of the thyroid. 
Introduction 
Proto-oncogenes are thought to have regulatory roles in 
normal cell proliferation and differentiation (1,2). They may 
contribute to the development and/or maintenance of the 
malignant phenotype, when there is an alteration of their 
function. They are overexpressed in a wide variety of human 
cancers (3). In some cases tumor aggressivity and state of 
differentiation have been correlated to the expression of 
certain oncogenes (3). 
The study of oncogene expression in the thyroid gland 
could be of particular interest, due to the existence of a wide 
range of both hyperplastic and neoplastic growth 
abnormalities, which are very common and are often 
subjected to surgical removal, ras oncogenes in particular 
have been found to be activated by qualitative (4) or 
quantitative (5-7) changes. 
In this study we report data on the expression of ras-
oncogene in benign hyperplastic or inflammatory lesions of 
the goiter in benign and malignant thyroid tumors. Our data 
show no significant differences in the expression of ras-
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oncogene between benign and malignant lesions. The 
overexpression in proliferative areas generally suggests the 
possible involvement of ras-oncogene in the trophic hormone 
control of the thyroid. 
Materials and methods 
The study was based on 66 cases of both benign and 
malignant conditions of thyroid. The tissue samples were 
collected from surgically removed thyroid lobes of patients 
subjected to either partial or total thyroidectomy. The cases 
included 16 nodular goiters (10 were of 'parenchymatous' 
type whereas the other 6 were of architecturally 
macrofollicular 'colloid' type), 2 cases of Grave's disease, 4 
cases of Hashimoto's thyroiditis, 5 follicular adenomas and 
39 cases of thyroid cancer and the following types of 
carcinomas: 23 papillary, 7 follicular, 8 medullary and 1 
anaplastic. In 26 cases of thyroid the non-tumorous 
parenchyma appeared normal whereas in the 13 remaining 
tumors changes of lymphocytic thyroiditis of varying degree 
were demonstrable in the non-tumorous tissue. 
The histological diagnosis was based on sections stained 
with H and E. The expression of H-ras-oncogene was studied 
on formalin-fixed and paraffin-embedded tissue sections by 
detection of ras p21 protein with the use of a 3-step 
immunoperoxidase technique as previously described (5). 
Paraffin sections were mounted on slides, incubated at 60°C 
for 24 hours and deparaffinized in xylene. The expression of 
the Η-ras oncogene was examined in the sections of all cases 
with benign and malignant lesions as well as in the 'normal' 
parenchyma observed in the vicinity of thyroid tumors. The 
staining pattern was graded as negative or equivocal (±), 
moderate (+) or intense (++). 
Results 
The expression of Η-ras oncogene was demonstrable by 
diffuse cytoplasmic immunoreactivity for ras p21 in the 
epithelial follicular cells or in the carcinomatous cells focally 
or in all regions of the examined tissue (Fig. 1). The non-
tumorous parenchyma adjacent to follicular adenomas and to 
follicular and papillary carcinomas having normofollicular 
structure without any infiltration by inflammatory cells 
showed little or no reactivity for ras p21 (Fig. 2). The 
staining in the non-tumorous thyroid tissue by the presence 
of medullary carcinoma was more intense than by the 
presence of follicle cell-carcinomas. All cases of nodular 
108 TSELENI-BALAFOUTA et al: ras p21 IN THYROID LESIONS 
V · * w - ' Afe * ~ •' *" ' ' 
' ; · • ; ' • • · · · • ' * · * ~ 
' * · . · 
» -«*. 
••."Λ' 
Figure 1. Papillary carcinoma of the thyroid. Intense (++) immunostaining Figure 4. Hashimoto's thyroiditis. Positive (+) immunostaining for ras p21 
for ras p21 in the cytoplasm of the carcinoma cells (X136). of the metaplastic oxyphilic follicular cells (X136). 
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Figure 2. Papillary carcinoma of the thyroid. Intense (++) immunostaining Figure 5. Follicular carcinoma of the thyroid, oxyphilic variant. Focally 
for ras p21 in the tumor cells and negative immunostaining in intense (++) immunostaining for ras p21 (X340). 
macrofollicular areas of the adjacent parenchyma (XI36). 
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Figure 3. Nodular goiter of the thyroid. Intense (++) immunostaining for ras 
p21 in microfollicular areas and negative staining in macrofollicular areas 
(XI36). 
goiter with focally or diffuse microfollicular ('adenomatous') 
pattern showed moderate to intense immunoreactivity 
(Fig. 3). Large epithelial cells in colloid-filled follicles were 
generally negative in ras expression as was demonstrable in 
the cases of 'colloid' goiters. Both cases of Crave's disease 
expressed moderate ras p21 as well as all cases of 
Hashimoto's thyroiditis, where the expression was even more 
intense particularly in cells with oxyphilic metaplasia (Fig. 4). 
Most of the neoplastic thyroid lesions expressed H-ras 
oncogene. The benign lesions (adenomas) showed slight or 
moderate immunoreactivity. Their malignant counterparts 
(follicular carcinomas) showed immunoreactivity to a 
slightly lesser extent (Fig. 5). The majority of papillary 
carcinomas showed strong staining for ras p21 and in only 2 
cases no reaction was demonstrable. No significant 
differences were found in the staining pattern of the papillary 
carcinoma related to any histological characteristics, grade of 
differentiation, or stage of the disease. A summary of the 
immunohistological analysis of ras p21 expression in 
normal, benign and malignant thyroid lesions is shown in 
Table I. Finally, the ras p21 expression was weak in 
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Table I. Immunohistochemical analysis of ras p21 
expression in normal, benign and malignant thyroid lesions. 
Histological type 
of thyroid specimen no 
Normal adjacent to 
papillary carcinoma 
follicular carcinoma 
medullary carcinoma 
Benign 
Nodular goiter 
'parenchymatous' 
'colloid' 
Grave's disease 
Hashimoto's thyroiditis 
Follicular adenoma 
Malignant carcinoma 
Papillary 
Follicular, 
Medullary 
Anaplastic 
Total 
. of cases 
14 
10 
6 
10 
6 
2 
4 
5 
23 
7 
8 
1 
Staining intensity 
no. of 
± 
13(93) 
10(100) 
3(50) 
0 
6(100) 
-
-
2(40) 
5(22) 
4(57) 
5(62) 
1(100) 
cases (%) 
+ 
1(7) 
-
2(35) 
7(70) 
-
2(100) 
1(25) 
3(60) 
12(52) 
3(43) 
1(13) 
-
++ 
-
-
1(17) 
3(30) 
-
-
3(75) 
-
6(26) 
-
2(25) 
-
medullary carcinomas, while no expression of ras p21 was 
found in the one case of anaplastic carcinoma (of giant cell 
type). 
Discussion 
Thyroid glands subjected to surgical excision exhibit 
hyperplastic, inflammatory or neoplastic changes. Thus, the 
most 'normal' tissue that can be obtained by the pathologist 
is non-tumorous thyroid parenchyma from glands resected 
for the presence of a tumor, though the possibility of 
influence from the tumor tissue cannot be excluded. 
The normofollicular thyroid parenchyma adjacent to 
follicular cell tumors (papillary and follicular carcinomas) 
which we examined showed only weak expression of ras-
oncogenes or no expression at all, which is in agreement with 
reports of others (6,7) whereas the 'normal' thyroid tissue 
adjacent to medullary carcinoma showed moderate 
immunoreactivity for ras p21. This enhanced expression 
could be the result of epithelial alterations due to unknown 
peptides secreted by the neuroendocrine tumor cells. 
Apparent enhanced expression of the ras-oncogene was 
demonstrable in most benign proliferative processes which 
produce goiters e.g. nodular hyperplasia, Crave's disease and 
Hashimoto's thyroiditis. Cell proliferation seemed to be the 
main histologic feature related to increased expression of 
ras-genes since the immunoreactivity was more intense in 
tissues with prominent hyperplasia, such as Grave's disease 
and 'adenomatous' areas in nodular hyperplasia. The intense 
staining in Hashimoto's thyroiditis could be explained by the 
fact that in many cases of Hashimoto's thyroiditis cell 
proliferation can be prominent. Therefore, the intensive 
immunoreactivity for ras p21 of the oxyplilic cells suggests 
that oxyphilic metaplasia does not represent a degenerative 
change in Hashimoto's thyroiditis. Our observations are in 
accordance with previous studies in rat thyroid carcinoma 
lines which have shown that TSH stimulates proto-oncogene 
expression (8). 
The regulation of ras proto-oncogenes in normal thyroid 
tissue at different stages of differentiation is still unknown. 
Although ras oncogene mutations have been associated with 
thyroid neoplasia (9-13) it remains difficult to assess whether 
overexpression of ras-oncogenes could cause, or be a 
consequence of a carcinoma. We observed a significant 
overexpression of ras-oncogene in well-differentiated 
follicular-cell carcinoma, and even more intense 
overexpression in papillary carcinoma. We did not find, 
however, the elevated apical surface expression of the ras 
product reported by others (7). It is of interest that, the ras 
p21 expression in follicular adenomas was slightly more 
increased when compared to the malignant counterpart 
(follicular carcinoma). A similar finding has been reported 
for colon adenomas, where the expression for ras-oncogene 
was elevated as compared to that found in colon carcinoma 
(14,15). The similarity in the ras-oncogene expression of 
cellular hyperplastic nodules, follicular adenomas and 
follicular carcinomas suggest that ras p21 .expression is 
unable to predict the potential biological behaviour of the 
examined lesions. 
Another interesting finding was the observation that in 
medullary carcinoma ras p21 was expressed weakly as 
compared to the follicular cell carcinoma. Medullary 
carcinoma is a neuroendocrine tumor located in the thyroid 
gland and is characterized clinically and biochemically by its 
neurosecretory properties. It has been shown that, when a 
mutated ras-gene is transfected into a neuroendocrine small-
cell lung carcinoma can change its phenotype to that 
suggesting a non-small cell lung carcinoma without 
neuroendocrine properties (16). This observation suggests 
that, ras-oncogene is not related to the neuro-endocrine 
differentiation. 
Long term prognosis of well-differentiated follicular-cell 
thyroid carcinoma is favourable, modulated by several 
parameters such as age, histologic characteristics and sex 
(17). On the contrary, undifferentiated carcinoma or 
carcinoma with an anaplastic component are very aggressive 
tumors with rapid progression and fatal outcome. 
A relationship has been sought between the over-
expression of oncogenes and the prognosis of patients with 
thyroid cancers by using diverse prognostic indices (18). In 
our study we have not found any significant differences in 
the expression of ras oncogene in well-differentiated 
carcinoma when compared to prognostic parameters, such as 
size and extension of primary tumor, histological features or 
presence of metastases. 
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